Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$55.0 million.

  • Tg Therapeutics' Net Cash Flow fell 148.74% to -$55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.7 million, marking a year-over-year decrease of 370.86%. This contributed to the annual value of $87.0 million for FY2024, which is 1029.31% up from last year.
  • Latest data reveals that Tg Therapeutics reported Net Cash Flow of -$55.0 million as of Q3 2025, which was down 1,735.01% from -$3.0 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Net Cash Flow high stood at $112.9 million for Q3 2024, and its period low was -$113.2 million during Q1 2022.
  • In the last 3 years, Tg Therapeutics' Net Cash Flow had a median value of -$15.9 million in 2024 and averaged -$2.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 1,083.02% in 2021, then surged by 244.84% in 2023.
  • Over the past 5 years, Tg Therapeutics' Net Cash Flow (Quarterly) stood at -$27.6 million in 2021, then soared by 72.66% to -$7.6 million in 2022, then slumped by 667.56% to -$58.0 million in 2023, then surged by 72.53% to -$15.9 million in 2024, then crashed by 148.74% to -$55.0 million in 2025.
  • Its Net Cash Flow was -$55.0 million in Q3 2025, compared to -$3.0 million in Q2 2025 and -$47.8 million in Q1 2025.